A combination therapy that adds a recently approved drug to the current standard of care for newly diagnosed acute myeloid ...

Revumenib shows promise for high-risk patients with acute myeloid leukemia (AML) with specific genetic mutations, ...

An artificial intelligence (AI)-driven machine learning model was refined and validated internationally to accurately classify acute leukemia subtypes from routine laboratory data, according to Merlin ...

A combination therapy that adds a recently approved drug to the current standard of care for newly diagnosed acute myeloid ...

Acute myelogenous leukemia, or AML, remains one of the most aggressive blood cancers. Each year, around 44,000 people in the ...

Johnson & Johnson announced new Phase 1b data showing antileukemic activity and a safety profile for bleximenib in ...